Under-representation of key demographic groups in opioid use disorder trials
Background: The extent to which clinical trials of medications for opioid use disorder (MOUD) are representative or not is unknown. Some patient characteristics modify MOUD effectiveness; if these same characteristics differ in distribution between the trial population and usual-care population, thi...
Main Authors: | Kara E. Rudolph, Matthew Russell, Sean X. Luo, John Rotrosen, Edward V. Nunes |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-09-01
|
Series: | Drug and Alcohol Dependence Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772724622000592 |
Similar Items
-
Lipid‐Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta‐Analysis of Exclusion Criteria
by: Martina Aeschbacher‐Germann, et al.
Published: (2023-01-01) -
Clinical drug trials in general practice: how well are external validity issues reported?
by: Anja Maria Brænd, et al.
Published: (2017-12-01) -
Identification of tools used to assess the external validity of randomized controlled trials in reviews: a systematic review of measurement properties
by: Andres Jung, et al.
Published: (2022-04-01) -
Commentary: On the levels of patient selection in registry-based randomized controlled trials
by: Florian Lasch, et al.
Published: (2019-02-01) -
Telemedication for Opioid Use Disorder: A New Approach for Treatment
by: Rebecca A. Georgiadis, et al.
Published: (2023-11-01)